Our Technology

SWEET™ is the abbreviation for ‘Shock Wave Exosome Engineering Technology’. SWEET™ is an innovative platform technology for the production of exosome-based drug delivery system using Extracorporeal Shock Wave (ESW). Our SWEET™ is a versatile platform technology that can apply various kind of exosomes and target molecules (siRNA, miRNA, or protein).

We believe that our innovative SWEET™ platform allows us to generate target molecule-encapsulated exosome with high loading efficiency that can be applied to various diseases with significant medical unmet needs. Therefore, SWEET™ platform have high potential to be applied for infinite pipelines depending on the source of exosomes and cargo materials.

Exollence Biotechnology Co., Ltd. provides the exosome-based drug delivery platform technology. If you have target molecules (siRNA, miRNA, or protein) of interest that you want to load into exosome, please contact to us and discuss your project.

Patent

  • Delivery method of target material into extracellular vesicles using extracorporeal shockwave
    (United States, May. 19, 2020).
  • Delivery method of target material into extracellular vesicles using extracorporeal shockwave
    (Republic of Korea, May. 06, 2020).
  • Method for secretion of extracellular vesicles from cells and tissues using shock wave
    (United States, Nov. 13, 2018).
  • Method for secretion of extracellular vesicles from cells and tissue using shock wave
    (Republic of Korea, Mar. 20, 2017).